Rallybio Corporation (RLYB) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$14.66
Price Target
—
Target Range
— — —
Analyst Rating
Buy
Forward P/E—
Trailing P/E-1.4x
Forward PEG—
Implied Growth-114.6%
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
RLYB Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Rallybio Corporation (RLYB) has a Wall Street consensus price target of N/A, based on estimates from 8 covering analysts. The company has a market capitalization of $83M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, RLYB trades at a trailing P/E of -1.4x. Analysts expect EPS to grow -114.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+45.5%
Avg Forward P/E50.4x
Peers with Coverage9 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $5.5B | $27.22 | $45.50 | +67.2% | Buy | — | 23 |
 PRAXPraxis Precision Medicines, Inc. | $9.6B | $333.28 | $544.40 | +63.3% | Buy | — | 16 |
 KYMRKymera Therapeutics, Inc. | $6.9B | $84.63 | $117.06 | +38.3% | Buy | — | 26 |
 ARQTArcutis Biotherapeutics, Inc. | $2.6B | $20.66 | $35.50 | +71.8% | Buy | 77.6x | 12 |
 TPSTTempest Therapeutics, Inc. | $55M | $1.97 | — | — | — | — | — |
 RVMDRevolution Medicines, Inc. | $30.3B | $142.51 | $154.80 | +8.6% | Buy | — | 22 |
 ALNYAlnylam Pharmaceuticals, Inc. | $39.5B | $295.91 | $445.67 | +50.6% | Buy | 44.2x | 52 |
 RAREUltragenyx Pharmaceutical Inc. | $2.6B | $26.13 | $51.50 | +97.1% | Buy | — | 33 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $8.7B | $296.70 | $332.75 | +12.2% | Buy | 39.3x | 17 |
Upside Potential Comparison
RAREARQTIMVTPRAXALNYKYMRKRYSRVMDSee RLYB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RLYB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RLYB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRLYB — Frequently Asked Questions
Quick answers to the most common questions about buying RLYB stock.
What is the RLYB stock price target for 2026?
The consensus price target for RLYB is $N/A, close to the current price of $14.66 (N/A% implied move). Based on 8 analyst estimates, the stock appears fairly valued near current levels.
Is RLYB a buy, sell, or hold?
RLYB has a consensus rating of "Buy" based on 8 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is RLYB stock overvalued or undervalued?
RLYB's current price is $14.66 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can RLYB stock go?
The most bullish Wall Street analyst has a price target of $N/A for RLYB, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover RLYB stock?
RLYB is moderately covered, with 8 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the RLYB stock forecast?
The 12-month RLYB stock forecast based on 8 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
Should I buy RLYB stock?
RLYB appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do RLYB price targets vary so much?
RLYB analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.